SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-080497
Filing Date
2024-07-02
Accepted
2024-07-02 16:20:09
Documents
13
Period of Report
2024-06-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atos-20240627.htm   iXBRL 8-K 94179
2 EX-3.1 atos-ex3_1.htm EX-3.1 10976
3 EX-10.1 atos-ex10_1.htm EX-10.1 155742
  Complete submission text file 0000950170-24-080497.txt   435724

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20240627.xsd EX-101.SCH 44882
15 EXTRACTED XBRL INSTANCE DOCUMENT atos-20240627_htm.xml XML 5960
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

IRS No.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 241095638
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)